These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 28249088)

  • 1. BRAF V600E Mutation in Involuting Nevus in a Patient Treated With Vemurafenib.
    Millán-Cayetano JF; Fernández-Canedo I; Blázquez-Sánchez N; Fúnez-Liébana R; de Troya-Martín M
    JAMA Dermatol; 2017 Jun; 153(6):605-607. PubMed ID: 28249088
    [No Abstract]   [Full Text] [Related]  

  • 2. BRAFV600E mutation status of involuting and stable nevi in dabrafenib therapy with or without trametinib.
    McClenahan P; Lin LL; Tan JM; Flewell-Smith R; Schaider H; Jagirdar K; Atkinson V; Lambie D; Prow TW; Sturm RA; Soyer HP
    JAMA Dermatol; 2014 Oct; 150(10):1079-82. PubMed ID: 24695877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vemurafenib in Chinese patients with BRAF
    Si L; Zhang X; Xu Z; Jiang Q; Bu L; Wang X; Mao L; Zhang W; Richie N; Guo J
    BMC Cancer; 2018 May; 18(1):520. PubMed ID: 29724167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distribution of BRAF T1799A(V600E) mutations across various types of benign nevi: implications for melanocytic tumorigenesis.
    Wu J; Rosenbaum E; Begum S; Westra WH
    Am J Dermatopathol; 2007 Dec; 29(6):534-7. PubMed ID: 18032947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
    Ravnan MC; Matalka MS
    Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analytical performance of a real-time PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel BRAF inhibitor vemurafenib in metastatic melanoma.
    Halait H; Demartin K; Shah S; Soviero S; Langland R; Cheng S; Hillman G; Wu L; Lawrence HJ
    Diagn Mol Pathol; 2012 Mar; 21(1):1-8. PubMed ID: 22306669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response in a child with a BRAF V600E mutated desmoplastic infantile astrocytoma upon retreatment with vemurafenib.
    van Tilburg CM; Selt F; Sahm F; Bächli H; Pfister SM; Witt O; Milde T
    Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29230924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High incidence of naevi-associated BRAF wild-type melanoma and dysplastic naevi under treatment with the class I BRAF inhibitor vemurafenib.
    Göppner D; Müller J; Krüger S; Franke I; Gollnick H; Quist SR
    Acta Derm Venereol; 2014 Sep; 94(5):517-20. PubMed ID: 24531394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular platforms utilized to detect BRAF V600E mutation in melanoma.
    Curry JL; Torres-Cabala CA; Tetzlaff MT; Bowman C; Prieto VG
    Semin Cutan Med Surg; 2012 Dec; 31(4):267-73. PubMed ID: 23174497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRAF(V600) mutation levels predict response to vemurafenib in metastatic melanoma.
    Lebbé C; How-Kit A; Battistella M; Sadoux A; Podgorniak MP; Sidina I; Pages C; Roux J; Porcher R; Tost J; Mourah S
    Melanoma Res; 2014 Aug; 24(4):415-8. PubMed ID: 24933605
    [No Abstract]   [Full Text] [Related]  

  • 11. Melanoma with BRAF Mutation in Circulating Cell-free DNA despite no Mutation in the Primary Lesion: A Case Report.
    Ashida A; Uhara H; Mikoshiba A; Sakaizawa K; Kumagai N; Koga H; Okuyama R
    Acta Derm Venereol; 2016 Jan; 96(1):128-9. PubMed ID: 26123241
    [No Abstract]   [Full Text] [Related]  

  • 12. Detection of the BRAF V600E mutation in melanocytic lesions using the ligase detection reaction.
    Turner DJ; Zirvi MA; Barany F; Elenitsas R; Seykora J
    J Cutan Pathol; 2005 May; 32(5):334-9. PubMed ID: 15811117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Separating Response of Tumor and non-Tumor Cells to Drug
    Kleinpoppen M; Moebius C; Grupp K; Kluwe L; Blessmann M
    Anticancer Res; 2019 Apr; 39(4):1777-1783. PubMed ID: 30952717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRAF V600E Mutations in Nevi and Melanocytic Tumors of Uncertain Malignant Potential.
    Seitz-Alghrouz R; Hidalgo JV; Kayser C; Kreutz C; Technau-Hafsi K; Diaz C; von Deimling A; Timmer J; Werner M; Malkovsky M; Fisch P
    J Invest Dermatol; 2018 Nov; 138(11):2489-2491. PubMed ID: 29775633
    [No Abstract]   [Full Text] [Related]  

  • 15. Induction vemurafenib followed by consolidative radiation therapy for surgically incurable melanoma.
    Seeley AR; De Los Santos JF; Conry RM
    Melanoma Res; 2015 Jun; 25(3):246-51. PubMed ID: 25746037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High BRAF mutation frequency does not characterize all melanocytic tumor types.
    Saldanha G; Purnell D; Fletcher A; Potter L; Gillies A; Pringle JH
    Int J Cancer; 2004 Sep; 111(5):705-10. PubMed ID: 15252839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is it good or bad to find a BRAF mutation?
    Flaherty KT
    J Clin Oncol; 2011 Apr; 29(10):1229-30. PubMed ID: 21343552
    [No Abstract]   [Full Text] [Related]  

  • 18. Patient-derived tumor xenograft model to guide the use of BRAF inhibitors in metastatic melanoma.
    Guerreschi P; Scalbert C; Qassemyar A; Kluza J; Ravasi L; Huglo D; Martinot-Duquennoy V; Formstecher P; Marchetti P; Mortier L
    Melanoma Res; 2013 Oct; 23(5):373-80. PubMed ID: 23852164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A patient with malignant pleural mesothelioma carrying BRAF V600E mutation responding to vemurafenib.
    Chen Y; Chen B; Zhu X; Zhong J
    Lung Cancer; 2018 Feb; 116():96-98. PubMed ID: 29146159
    [No Abstract]   [Full Text] [Related]  

  • 20. BRAF wild-type melanoma in situ arising in a BRAF V600E mutant dysplastic nevus.
    Tan JM; Lin LL; Lambie D; Flewell-Smith R; Jagirdar K; Schaider H; Sturm RA; Prow TW; Soyer HP
    JAMA Dermatol; 2015 Apr; 151(4):417-21. PubMed ID: 25607474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.